No Strategy Rethink At Merck KGaA After Late-Stage Failures

 
• By Andrew McConaghie

Investors were keen to hear fresh thinking after two Phase III failures, but Merck remains focused on bolstering its life science services business ahead of its biopharma division.

Merck KGaA Darmstadt
(Merck KGaA)

More from Earnings

More from Business